The Science Behind Kratom and Mood: What the Research Actually Shows

Nearly one in five American adults deals with a mental health condition in any given year, and many are looking beyond conventional treatments for relief. Kratom (Mitragyna speciosa), a tree native to Southeast Asia, has become one of the more closely studied botanicals in this space. A growing set of animal studies and user surveys suggests it interacts with several neurochemical systems tied to mood, anxiety, and emotional regulation. This article walks through what the peer-reviewed evidence actually says — and where the gaps remain significant.

One note up front: there are no randomized controlled trials of kratom in humans for depression or anxiety. Everything below comes from lab studies in animals or from surveys of people who already use kratom. That’s a meaningful limitation, and anyone managing a diagnosed mental health condition should talk to a physician before trying kratom, especially given the risk of drug interactions with psychiatric medications.

How kratom interacts with the brain’s mood systems

Kratom leaves contain more than 40 different alkaloids, but two get most of the credit for mood-related effects: mitragynine, which makes up roughly 60–66% of the alkaloid content, and 7-hydroxymitragynine (7-HMG). Two lesser-known compounds, paynantheine and speciogynine, also appear to play a role.

The opioid receptor connection

Mitragynine and 7-HMG act as partial agonists at mu-opioid receptors — the same receptors that respond to the body’s own endorphins. What makes them different from typical opioids is that they show a bias toward activating G-protein signaling rather than the beta-arrestin pathway, which is more closely linked to side effects like respiratory depression. Researchers think this biased signaling may explain why kratom can lift mood and ease anxiety without producing the same side-effect profile as classical opioid drugs. Kratom’s alkaloids also touch kappa- and delta-opioid receptors, both of which help regulate stress responses and emotional tone.

Serotonin pathways

Mitragynine’s chemical structure resembles serotonin, and studies have found it interacts with several serotonin receptor subtypes — 5-HT1A, 5-HT2C, and 5-HT7 — all of which play a role in mood and anxiety regulation. Separately, paynantheine and speciogynine act on the 5-HT1A receptor, the same target used by buspirone, a prescription anti-anxiety medication. This gives researchers a plausible explanation for kratom’s calming effects that doesn’t depend on opioid receptors at all.

Dopamine and GABA involvement

Animal research points to dopamine as another piece of the puzzle. In one study, mitragynine’s anxiety-reducing effects disappeared when researchers blocked D1 and D2 dopamine receptors with the drugs SCH 23390 and sulpiride. The same anxiolytic effect also vanished when researchers used flumazenil, a drug that blocks GABA-benzodiazepine receptors. Together, these findings suggest kratom’s calming effects come from several systems working in tandem — opioid, serotonin, dopamine, and GABA — rather than a single mechanism the way most psychiatric drugs work.

Alkaloid profiles at a glance

Alkaloid	Main receptor targets	Relevance to mental health
Mitragynine	MOR (biased partial agonist), 5-HT1A, 5-HT2C, D1, D2, alpha-2 adrenergic, GABA	Mood elevation, anxiety reduction, antidepressant-like effects in animal models
7-Hydroxymitragynine	MOR (partial agonist, roughly 13x morphine’s potency), kappa-opioid	Sedation and anxiety relief at higher doses
Paynantheine	5-HT1A agonist, smooth muscle relaxant	Possible antidepressant and relaxing effects, similar mechanism to buspirone
Speciogynine	5-HT1A agonist, smooth muscle relaxant	May contribute to the calming effects associated with green-vein strains
Corynantheidine	Opioid antagonist/partial agonist	May temper or balance the overall opioid effect

What the research says about kratom and depression

Depression is one of the most common reasons people report using kratom, and animal research has started to build a case for why.

Lab findings

In the Porsolt forced swim test — a standard screening tool researchers use to test antidepressant-like activity in animals — a methanolic extract of kratom leaf reduced immobility time in mice at several doses (100, 200, and 400 mg/kg), producing results comparable to conventional antidepressants. Researchers linked this effect to mitragynine’s action on serotonin receptors, particularly 5-HT1A and 5-HT2C. Similar results turned up in the tail suspension test, another standard rodent model for depression research.

What surveys tell us

A 2017 survey led by researcher Oliver Grundmann collected responses from 8,049 kratom users in the US. Sixty-six percent said they used kratom for an emotional or mental health condition, with depression ranking among the top three reasons alongside anxiety and pain. A separate 2020 survey out of Johns Hopkins, involving 2,798 users, found that about 65% used kratom for anxiety or depression, and 91% of those rated it effective.

A 2018 systematic review by Swogger and Walsh looked across the available literature and concluded that kratom “enhances mood and relieves anxiety among many users,” and that withdrawal symptoms tend to be milder than those from classical opioids for most people who use it.

Where the evidence falls short

Most of what we know comes from animal studies, and results in mice don’t always translate to humans. No controlled clinical trials have tested kratom for depression. Survey data has its own problems — respondents are often recruited from communities that already favor kratom use, which skews the results, and there’s no way to separate genuine benefit from placebo effect.

A 2025 analysis by Yang and colleagues looked at 403 men with a history of methamphetamine use and found that those who also used kratom reported fewer depressive symptoms, with the effect tracking dose and frequency. That’s a correlation, not proof of cause and effect, but it lines up with the broader pattern seen in other surveys.

On the other side, a 2021 case report from Müller and colleagues described a 63-year-old patient who had managed major depression and generalized anxiety with kratom for seven years — until acute stress overwhelmed that approach, requiring detox and a switch to conventional psychiatric treatment. Both of these findings point to the same conclusion: kratom is not a substitute for professional mental health care.

What the research says about kratom and anxiety

Anxiety disorders are the most common mental health condition worldwide, and “kratom for anxiety” is a frequent search topic. The evidence here follows the same pattern as depression research — limited in rigor, but pointing in a consistent direction.

Animal studies

A 2014 study tested mitragynine’s anxiety-reducing effects in rats using two standard behavioral tests: the open-field test and the elevated plus-maze. At doses of 10, 20, and 40 mg/kg, mitragynine increased the animals’ willingness to explore open, exposed areas — a sign of reduced anxiety — with effects comparable to a 10 mg/kg dose of diazepam (Valium).

When researchers blocked four different receptor systems — using naloxone for opioid receptors, flumazenil for GABA-benzodiazepine receptors, sulpiride for D2 dopamine receptors, and SCH 23390 for D1 dopamine receptors — the anxiety-reducing effect disappeared in each case. That suggests kratom’s calming action depends on several systems working together rather than any single pathway.

What users report

A qualitative analysis of firsthand accounts posted to Erowid.org found anxiety reduction to be a recurring theme, with users describing relief from social anxiety, generalized worry, and restlessness — often without the mental fog associated with benzodiazepines.

A 2024 systematic review and meta-analysis confirmed that kratom users frequently report relying on it for depression, anxiety, and PTSD symptoms, though the study’s authors were clear that prospective clinical trials are needed before anyone draws firm conclusions.

Do different strains matter?

There’s no clinical research comparing strains directly, but users consistently describe red vein kratom — which tends to have a higher ratio of 7-HMG to mitragynine — as better suited for stress relief and relaxation. Green strains are often described as offering more balanced mood support with less sedation. Take these patterns as anecdotal rather than clinically confirmed.

Does kratom show antipsychotic-like effects?

One less-explored area of research looks at whether kratom might have antipsychotic properties. A 2016 study published in Frontiers in Pharmacology found that kratom leaf extract reduced apomorphine-induced climbing behavior in mice — a standard model for positive psychotic symptoms — and also improved social interaction in ketamine-treated mice, a model used to study negative symptoms like social withdrawal.

That combination is notable because most conventional antipsychotic drugs only address positive symptoms, not negative ones. Researchers attribute the effect to kratom’s action on dopamine D2 receptors and serotonin 5-HT2C receptors — the same targets used by atypical antipsychotics such as clozapine and risperidone.

Again, this is animal research only. No human studies have examined kratom for psychotic disorders, and people with psychotic conditions should not use it as a replacement for prescribed antipsychotic medication. Case reports have documented psychiatric complications, including manic episodes, in patients with complicated psychiatric histories.

Why dose matters so much for mental health effects

One of kratom’s more clinically important features is that it behaves differently depending on how much you take. Low doses tend to act as a stimulant; higher doses lean sedative and anxiety-reducing. That distinction matters a lot if someone is trying to target a specific symptom.

Dose range	Main effects	Likely mechanism	Relevance to mental health
Low (1–3 g)	Stimulation, alertness, sociability, motivation	Adrenergic and dopaminergic activity, mitragynine-dominant	May help with motivation and low energy tied to depression
Moderate (3–5 g)	Balanced mood lift, mild anxiety relief, focus	Combined opioid, serotonin, and dopamine activation	Most commonly reported as the “sweet spot” for mood and anxiety
High (5–8 g)	Sedation, stronger anxiety relief, pain relief	Increased 7-HMG activity, deeper opioid receptor engagement	May help with severe anxiety, but side-effect risk rises noticeably
Very high (8+ g)	Heavy sedation, nausea, cognitive fog	Saturated opioid receptor activity	Returns diminish and side effects dominate — not recommended

The Grundmann survey backed up this pattern: negative effects, mainly nausea and constipation, rose sharply at doses of 5 grams or more and with 22 or more doses taken per week. For mood and anxiety purposes, the general recommendation is to stick to the lowest dose that works, typically somewhere in the 1–5 gram range.

What large surveys reveal about kratom and mental health

Surveys are the closest thing available to direct human evidence, even though they can’t prove kratom actually treats anything.

Study	Sample size	Key findings
Grundmann, 2017 (Drug & Alcohol Dependence)	8,049 users	66% used kratom for emotional or mental health reasons; depression and anxiety ranked in the top three uses alongside pain
Swogger et al., 2015 (Journal of Psychoactive Drugs)	161 Erowid reports	Mood improvement and anxiety reduction were among the most commonly cited benefits
Swogger & Walsh, 2018 (Drug & Alcohol Dependence)	Systematic review, 1960–2017	Kratom “enhances mood and relieves anxiety among many users”; withdrawal generally milder than classical opioids
Johns Hopkins survey, 2020 (Drug & Alcohol Dependence)	2,798 users	About 65% used kratom for anxiety or depression; 91% rated it effective
Yang et al., 2024 (European Addiction Research)	Systematic review and meta-analysis	Confirmed frequent self-reported use for depression, anxiety, and PTSD; called for clinical trials

The pattern across these surveys is consistent: a majority of kratom users report using it for mental health reasons and believe it helps. The limitations are just as consistent — self-selected samples, no clinical verification of diagnoses, no way to rule out placebo effects, and recruitment that often skews toward people already favorable to kratom.

The mental health risks of regular use

Any honest look at kratom needs to weigh the risks alongside the potential benefits.

Dependence and withdrawal

Regular kratom use can lead to physical dependence. Swogger and Walsh found that while withdrawal tends to be milder than with classical opioids, some users find it “highly uncomfortable,” making it hard to stop. Withdrawal symptoms — irritability, anxiety, restlessness, muscle aches, and low mood — can temporarily make the original symptoms worse.

Interactions with psychiatric medications

Kratom’s alkaloids are broken down mainly by the liver enzymes CYP3A4 and CYP2D6, which are also involved in metabolizing many psychiatric drugs. This creates real interaction risks:

• SSRIs and SNRIs: Kratom’s serotonergic activity adds to the body’s serotonin load, raising the risk of serotonin syndrome when combined.
• Benzodiazepines: Kratom can inhibit CYP3A4, which may raise benzodiazepine blood levels; combining the two also compounds central nervous system depression.
• Antipsychotics: CYP2D6 inhibition affects how the body processes drugs like aripiprazole, risperidone, and quetiapine.
• MAOIs: The combined serotonergic load makes concurrent use unsafe.

Psychiatric complications

Case reports describe new or worsening psychiatric symptoms tied to kratom use, including manic episodes in patients with PTSD or depression. People with bipolar disorder, psychotic disorders, or complicated psychiatric histories should be especially cautious.

Risk rises with dose

Much of kratom’s mental health risk tracks with dose. At 1–3 grams, opioid receptor activation is fairly mild. Push toward 6–8 grams or more, and that activation deepens, along with the severity of withdrawal if someone stops. Sticking to the lowest effective dose is one of the more direct ways to reduce this risk.

Who should steer clear of kratom for mental health reasons

• Anyone currently taking psychiatric medication — SSRIs, SNRIs, MAOIs, antipsychotics, or benzodiazepines — should talk to their prescribing doctor first
• People with bipolar disorder, given reported risk of manic episodes
• Anyone with a history of psychotic disorders
• Pregnant or breastfeeding individuals
• People with a history of substance use disorder (possible under professional supervision, but dependence risk is elevated)
• Anyone with active liver disease, since impaired liver function can raise alkaloid levels in the blood
• Anyone under 18

For those who choose to proceed anyway, the harm-reduction basics that come up consistently in the research and user community include: starting with just 1–2 grams, waiting at least 45 minutes before considering more, avoiding daily use, rotating strains to limit tolerance buildup, telling your doctor you’re using it, and never treating kratom as a replacement for professional mental health treatment.